Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 70, No 6 (2019)
Original paper
Submitted: 2019-07-22
Accepted: 2019-09-03
Published online: 2019-09-30
View PDF Download PDF file
Get Citation

Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis

Joanna Głogowska-Szeląg1, Beata Kos-Kudła1, Bogdan Marek1, Mariusz Nowak1, Lucyna Siemińska1
DOI: 10.5603/EP.a2019.0043
·
Pubmed: 31566247
·
Endokrynol Pol 2019;70(6):478-483.
Affiliations
  1. Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Poland

open access

Vol 70, No 6 (2019)
Original Paper
Submitted: 2019-07-22
Accepted: 2019-09-03
Published online: 2019-09-30

Abstract

Introduction: Osteoporosis and obesity are considered civilisation diseases. Menopause is a time of increased bone resorption and increased mass of adipose tissue. Adipocytokines secreted by the adipose tissue are believed to be a potential factor in the pathogenesis of osteoporosis.

Material and methods: The aim of this research was to assess leptin, adiponectin, and resistin secretion in obese postmenopausal women with osteoporosis and determine whether obesity might be a factor mitigating the risk of osteoporosis. The study involved 80 postmenopausal women with osteoporosis divided into groups: I with BMI of 30.0 34.9, obese; and II with BMI of 18–24.9, normoweight. Leptin, adiponectin and resistin concentrations were assessed, and bone mineral density (BMD) was measured in the L1-L4 section of the spine using the DXA densitometric method.

Results: The results of the comparison of the two groups indicate a statistically significant dependence in groups regarding leptin secretion; the group of obese women demonstrated significantly higher concentrations. No differences between the groups were demonstrated for adiponectin or resistin secretion.

Conclusions: Higher leptin concentration and a positive correlation with BMI was confirmed in obese postmenopausal women with osteoporosis. It was also demonstrated that BMD increases with growing BMI. No effect of obesity on the secretion of adiponectin or resistin in women with postmenopausal osteoporosis was found. From among the investigated adipocytokines, only leptin can be considered a bone tissue protective factor in postmenopausal women. 

Abstract

Introduction: Osteoporosis and obesity are considered civilisation diseases. Menopause is a time of increased bone resorption and increased mass of adipose tissue. Adipocytokines secreted by the adipose tissue are believed to be a potential factor in the pathogenesis of osteoporosis.

Material and methods: The aim of this research was to assess leptin, adiponectin, and resistin secretion in obese postmenopausal women with osteoporosis and determine whether obesity might be a factor mitigating the risk of osteoporosis. The study involved 80 postmenopausal women with osteoporosis divided into groups: I with BMI of 30.0 34.9, obese; and II with BMI of 18–24.9, normoweight. Leptin, adiponectin and resistin concentrations were assessed, and bone mineral density (BMD) was measured in the L1-L4 section of the spine using the DXA densitometric method.

Results: The results of the comparison of the two groups indicate a statistically significant dependence in groups regarding leptin secretion; the group of obese women demonstrated significantly higher concentrations. No differences between the groups were demonstrated for adiponectin or resistin secretion.

Conclusions: Higher leptin concentration and a positive correlation with BMI was confirmed in obese postmenopausal women with osteoporosis. It was also demonstrated that BMD increases with growing BMI. No effect of obesity on the secretion of adiponectin or resistin in women with postmenopausal osteoporosis was found. From among the investigated adipocytokines, only leptin can be considered a bone tissue protective factor in postmenopausal women. 

Full Text:

View PDF Download PDF file
Get Citation

Keywords

adipocytokines; obesity; osteoporosis; women; menopause

About this article
Title

Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis

Journal

Endokrynologia Polska

Issue

Vol 70, No 6 (2019)

Article type

Original paper

Pages

478-483

Published online

2019-09-30

Page views

1947

Article views/downloads

961

DOI

10.5603/EP.a2019.0043

Pubmed

31566247

Bibliographic record

Endokrynol Pol 2019;70(6):478-483.

Keywords

adipocytokines
obesity
osteoporosis
women
menopause

Authors

Joanna Głogowska-Szeląg
Beata Kos-Kudła
Bogdan Marek
Mariusz Nowak
Lucyna Siemińska

References (46)
  1. Compston J, Cooper A, Cooper C, et al. National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62(2): 105–108.
    CrossRefPubMed
  2. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis — its clinical features. J Am Med Assoc. 1941; 116: 2465–2474.
    CrossRef
  3. Zeng J, Li K, Gong Y, et al. Association of pro-inflammatory cytokines with QCT-measured bone mineral density and its gender difference in a Chinese population - a pilot study. Endokrynol Pol. 2019; 70(3): 248–254.
    CrossRefPubMed
  4. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000; 11(8): 669–674.
    CrossRefPubMed
  5. Oursler MJ, Landers JP, Riggs BL, et al. Oestrogen effects on osteoblasts and osteoclasts. Ann Med. 1993; 25(4): 361–371.
    CrossRefPubMed
  6. Ravn P, Cizza G, Bjarnason NH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999; 14(9): 1622–1627.
    CrossRefPubMed
  7. Liu Y, Song CY, Wu SS, et al. Novel adipokines and bone metabolism. Int J Endocrinol. 2013; 2013: 895045.
    CrossRefPubMed
  8. Reid IR. Fat and bone. Arch Biochem Biophys. 2010; 503(1): 20–27.
    CrossRefPubMed
  9. Albala C, Yauez M, Deroto E, et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996; 20(11): 1027–1032.
    PubMed
  10. Morcov C, Vulpoi C, Branisteanu D. Correlation between adiponectin, leptin, insulin-like growth factor-1 and bone mineral density in pre and post-menopausal women. Rev Med Chir Soc Med Nat Iasi. 2012; 116(3): 785–789.
    PubMed
  11. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013; 18: 12.
    CrossRefPubMed
  12. Biver E, Salliot C, Combescure C, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96(9): 2703–2713.
    CrossRefPubMed
  13. Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr. 2006; 83(1): 146–154.
    CrossRefPubMed
  14. Siemińska L, Cichoń-Lenart A, Kajdaniuk D, et al. Hormony płciowe i adipocytokiny u kobiet po menopauzie. Pol Merk Lek. 2006; XX(120): 727–729.
  15. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002; 175(2): 405–415.
    CrossRefPubMed
  16. Ben-Eliezer M, Phillip M, Gat-Yablonski G. Leptin regulates chondrogenic differentiation in ATDC5 cell-line through JAK/STAT and MAPK pathways. Endocrine. 2007; 32(2): 235–244.
    CrossRefPubMed
  17. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999; 140(4): 1630–1638.
    CrossRefPubMed
  18. Leibel RL. The role of leptin in the control of body weight. Nutr Rev. 2002; 60(10 Pt 2): S15–S9; discussion S68.
    CrossRefPubMed
  19. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002; 17(2): 200–209.
    CrossRefPubMed
  20. Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149(4): 331–335.
    CrossRefPubMed
  21. Horakova D, Stepanek L, Nagelova R, et al. Total and high-molecular-weight adiponectin levels and prediction of insulin resistance. Endokrynol Pol. 2018; 69(4): 375–380.
    CrossRefPubMed
  22. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006; 21(10): 1648–1656.
    CrossRefPubMed
  23. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004; 35(4): 842–849.
    CrossRefPubMed
  24. Lee WY, Rhee EJ, Oh KiW, et al. Identification of adiponectin and its receptors in human osteoblast-like cells and association of T45G polymorphism in exon 2 of adiponectin gene with lumbar spine bone mineral density in Korean women. Clin Endocrinol (Oxf). 2006; 65(5): 631–637.
    CrossRefPubMed
  25. Gomez R, Lago F, Gomez-Reino J, et al. Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. J Mol Endocrinol. 2009; 43(1): 11–18.
    CrossRefPubMed
  26. Douchi T, Yamamoto S, Oki T, et al. Difference in the effect of adiposity on bone density between pre- and postmenopausal women. Maturitas. 2000; 34(3): 261–266.
    CrossRefPubMed
  27. Tenta R, Kontogianni MD, Yiannakouris N. Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J Endocrinol Invest. 2012; 35(3): 306–311.
    CrossRefPubMed
  28. Silva HG, Mendonça LMC, Conceição FL, et al. Influence of obesity on bone density in postmenopausal women. Arq Bras Endocrinol Metabol. 2007; 51(6): 943–949.
    CrossRefPubMed
  29. Reid IR. Obesity and osteoporosis. Ann Endocrinol. 2006; 67: 125–129.
    CrossRefPubMed
  30. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2(1): 35–43.
    CrossRefPubMed
  31. Rosen CJ. Osteoporoza. Zasady rozpoznawania i leczenia. Springer PWN, Warszawa 1998: 16–22.
  32. Blain H, Vuillemin A, Guillemin F, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2002; 87(3): 1030–1035.
    CrossRefPubMed
  33. Lecke SB, Morsch DM, Spritzer PM. Leptin and adiponectin in the female life course. Braz J Med Biol Res. 2011; 44(5): 381–387.
    PubMed
  34. Ostlund RE, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab. 1996; 81(11): 3909–3913.
    CrossRefPubMed
  35. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005; 174(9): 5789–5795.
    CrossRefPubMed
  36. Sodi R, Hazell MJ, Durham BH, et al. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism. Clin Biochem. 2009; 42(13–14): 1375–1380.
    CrossRefPubMed
  37. Zoico E, Zamboni M, Bosello O. The consequences of aging on endocrine function of adipose tissue. Obes Metab. 2008; 4(1): 64–75.
  38. Kontogianni MD, Dafni UG, Routsias JG, et al. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res. 2004; 19(4): 546–551.
    CrossRefPubMed
  39. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46(4): 459–469.
    CrossRefPubMed
  40. Jürimäe J, Jürimäe T. Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int. 2007; 18(9): 1253–1259.
    CrossRefPubMed
  41. Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf). 2002; 56(6): 703–711.
    CrossRefPubMed
  42. Tenta R, Kontogianni MD, Yiannakouris N. Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J Endocrinol Invest. 2012; 35(3): 306–311.
    CrossRefPubMed
  43. Laughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (Lond). 2007; 31(3): 457–465.
    CrossRefPubMed
  44. Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care. 2003; 26(8): 2383–2388.
    CrossRefPubMed
  45. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
    CrossRefPubMed
  46. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab. 2004; 6(3): 163–170.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl